Camptothecin

Catalog No.S1288 Synonyms: NSC-100880

Camptothecin Chemical Structure

Molecular Weight(MW): 348.35

Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.

Size Price Stock Quantity  
USD 50 In stock
USD 110 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 19 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM in a cell-free assay. Phase 2.
Targets
Topo I [2]
(Cell-free assay)
0.68 μM
In vitro

Camptothecin, a plant alkaloid orignially isolated from Camptotheca acuminate in 1966. [1] Camptothecin is noted to halt cells during the S phase of mitosis. Camptothecin displays nanomolar potency in cytotoxicity against many human tumor cell lines, including HT29, LOX, SKOV3, and SKVLB, with IC50 values ranging from 37 nM to 48 nM. [2] In combination with TNF, Camptothecin induces apoptosis in primary mouse hepatocytes, with an IC50 value of 13 μM. Camptothecin also abrogated the TNF-induced NF-κB Activation, as well as the expression of TNF-receptor associated factor 2 (TRAF2), X-linked inhibitor of apoptosis protein (X-IAP), and FLICE-inhibitory protein (FLIP). [4] In HCT116 cells, Camptothecin (5 μM) induces proteasome-mediated degradation of mixed lineage leukemia 5 (MLL5) protein, which leads to phosphorylation of p53 at Ser392. [5] Due to the low solubility and adverse effects of Camptothecin, various Camptothecin analogues have been developed, and two of them, topotecan and irinotecan, has been approved by FDA and are used in cancer chemotherapy.

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKOV3 MnvVZ5l1d3SxeHnjbZR6KGG|c3H5 NVTsfmNoUUN3ME21NUBvVQ>? NEHIOXc6ODB|NUKw
SKVLB MkjpZ5l1d3SxeHnjbZR6KGG|c3H5 NV[1fG5CUUN3ME21N{BvVQ>? MUG5NFA{PTJy
HT29 NYX5epNi[3m2b4TvfIlkcXS7IHHzd4F6 MXzJR|UxRTh5Lkigcm0> M1rxXVkxODN3MkC=
KB NFrubGJkgXSxdH;4bYNqfHliYYPzZZk> NVTVSVhtUUN3ME24JI5O MWW5NFA{PTJy
A427 NXKwOmcxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlzYglEh|ryP NWLYUWlNTE2VTx?= MnrjTWM2OD1{NDDuUS=> NEHPfGo6QDd4MUGx
PC-3 M2DJS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NETGcZJ,OSEQvF2= MYnEUXNQ NYSzN2hQUUN3ME21O{BvVQ>? MXW5PFc3OTFz
K562adr NIfJU5NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXL+NUDPxE1? NYOxUIxlTE2VTx?= NX6zVVFJUUN3ME21O{BvVQ>? NGDyUpA6QDd4MUGx
MCF7mdr MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkWwglEh|ryP NXLa[I9ITE2VTx?= M12zOmlEPTB;Mz6xJI5O NXjWdG83QTh5NkGxNS=>
P388 Mlz4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYjJR|UxRTN{IH7N MofLNVA{PDZ7M{O=
P388CPT5 R M2XoVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXq2WJlMUUN3ME2yMlgh|ryP NHuwXXUyODN2NkmzNy=>
KBwt M{HaS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXfJR|UxRTRyIH7N M{HWNlExPDFzNEe2
KBMDR MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NG[xRllKSzVyPUewJI5O NXfHSHFiOTB2MUG0O|Y>
KBV20C MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkHPTWM2OD1|MDDuUS=> MoK1NVA1OTF2N{[=
KB7D MoLKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1;IUGlEPTB;M{Wgcm0> MVuxNFQyOTR5Nh?=
KBCamp MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHfsVZRKSzVyPUGuNFQh|ryP MWCxNFQyOTR5Nh?=
HT29 MoDpZ5l1d3SxeHnjbZR6KGG|c3H5 NXvaRlhPUUN3ME24NEBvVQ>? NF7TTHEyODh2MUiwPC=>
A549 MoO5Z5l1d3SxeHnjbZR6KGG|c3H5 NH;ISHNKSzVyPU[3JI5O Ml[5NVA5PDF6MEi=
T24 NVzzN29w[3m2b4TvfIlkcXS7IHHzd4F6 MoLHTWM2OD16ODDuUS=> M1jje|ExQDRzOEC4
HOP-62 M3HmRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUXJR|UxRTFyIH7N M1TKW|EyODJyMkiz
HCT-116 Ml7xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVPJR|UxRTNyIH7N NHP2cG4yOTB{MEK4Ny=>
SF-539 M3PESGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVrJR|UxRTFyIH7N MVqxNVAzODJ6Mx?=
UACC-62 NXHUSmNpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1Gx[WlEPTB;MUCgcm0> MVKxNVAzODJ6Mx?=
OVCAR-3 M1PlUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2WyN2lEPTB;MkKwJI5O NVnBNIw{OTFyMkCyPFM>
SN12C MV\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWnQfVdLUUN3ME2yNEBvVQ>? NYXQd3FsOTFyMkCyPFM>
DU-145 NFnlOIVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1nQOGlEPTB;MUCgcm0> MYixNVAzODJ6Mx?=
MDA-MB-435 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVjifWRSUUN3ME20NEBvVQ>? MV:xNVAzODJ6Mx?=
WiDr M2D0boN6fG:2b4jpZ4l1gSCjc4PhfS=> NWmzS2ZRTE2VTx?= NIXGS4RKSzVyPUG3JI5O MoqyNVE{OzR3Nkm=
A549 MnvaZ5l1d3SxeHnjbZR6KGG|c3H5 M4rtZ2ROW09? NUf1col[UUN3ME2xOEBvVQ>? MWqxNVM{PDV4OR?=
MKN45 NEnZeXNkgXSxdH;4bYNqfHliYYPzZZk> MXfEUXNQ MoHLTWM2OD1zNzDuUS=> MXWxNVM{PDV4OR?=
SK-OV-3 MmHwZ5l1d3SxeHnjbZR6KGG|c3H5 MmDVSG1UVw>? NYnSOJlbUUN3ME2yNEBvVQ>? NFTpWFMyOTN|NEW2PS=>
H128 MlHoZ5l1d3SxeHnjbZR6KGG|c3H5 NHu3VmdFVVOR MnrSTWM2OD1zODDuUS=> NV7CVGdlOTF|M{S1Olk>
SK-BR-3 M2jvRYN6fG:2b4jpZ4l1gSCjc4PhfS=> NXT5bpFJTE2VTx?= M3vnVGlEPTB;MkCgcm0> NFX6PHEyOTN|NEW2PS=>
LX-1 NWnTNYcy[3m2b4TvfIlkcXS7IHHzd4F6 MlXSSG1UVw>? NWLCd3BFUUN3ME2xNlAhdk1? MkXHNVE5PTh5M{e=
HCT116 NU\zPI9Y[3m2b4TvfIlkcXS7IHHzd4F6 NWPxXXp5TE2VTx?= MV7JR|UxRTlibl2= MoPzNVE5PTh5M{e=
A2780 NHTP[VNkgXSxdH;4bYNqfHliYYPzZZk> NGfkSYtFVVOR Mo\LTWM2OD12IH7N M2XKVlEyQDV6N{O3
IMR-32 NIn1RmJkgXSxdH;4bYNqfHliYYPzZZk> Mk\tglExKM7:TR?= MljySG1UVw>? M1rCRmlEPTB;Mj6yNUBvVQ>? M1\lfVEzPjF5OEm0
P388 MlPvZ5l1d3SxeHnjbZR6KGG|c3H5 M4L2XmlEPTB;MUOgcm0> MnfKNVI3OjByOEG=
Lewis NXXTZ3E4[3m2b4TvfIlkcXS7IHHzd4F6 NIjwd2tKSzVyPUOzJI5O MknZNVI3OjByOEG=
JLC Mn7yZ5l1d3SxeHnjbZR6KGG|c3H5 M1\QOWlEPTB;NT62JI5O M1HrXlEzPjJyMEix
HT-29 MmT4Z5l1d3SxeHnjbZR6KGG|c3H5 NHS1NmFKSzVyPUGuOEDPxE1? MnrCNVI3Ozl3NEG=
Caki-2 MXPjfZRwfG:6aXPpeJkh[XO|YYm= NF7NeI9KSzVyPUOuPVYh|ryP MmTENVI3Ozl3NEG=
A549 M{HPeYN6fG:2b4jpZ4l1gSCjc4PhfS=> NGO3V4RKSzVyPUKuOVMh|ryP Ml;UNVI3Ozl3NEG=
HEC-1-B NGHpNVBkgXSxdH;4bYNqfHliYYPzZZk> MYLJR|UxRThwNkSg{txO NE\lV4YyOjZ|OUW0NS=>
HL-60 MkDBZ5l1d3SxeHnjbZR6KGG|c3H5 MX3JR|UxRTZ4IH7N MnOwNVI3Ozl3NEG=
Col2 Mkn5Z5l1d3SxeHnjbZR6KGG|c3H5 M4[wOp4yKM7:TR?= M2\LcWVFPTB;NUegcm0> M1fyR|E2ODR|NEC3
HUVEC NXvNZ|lJ[3m2b4TvfIlkcXS7IHHzd4F6 M2HIeJ4yKM7:TR?= M1:4WmVFPTB;MkW4JI5O NVPBZpJTOTVyNEO0NFc>
KB NHm3bVJkgXSxdH;4bYNqfHliYYPzZZk> NGSzfmV,OSEQvF2= MVLFSFUxRTJ{IH7N M3;w[lE2ODR|NEC3
LCNaP M{fHXoN6fG:2b4jpZ4l1gSCjc4PhfS=> NVqxZ4dqhjFizszN M3TWWmVFPTB;Mkigcm0> M3rRb|E2ODR|NEC3
Lu1 MmOwZ5l1d3SxeHnjbZR6KGG|c3H5 MmXUglEh|ryP MnuwSWQ2OD1{OTDuUS=> MnjFNVUxPDN2MEe=
RPMI8402 M4DneoN6fG:2b4jpZ4l1gSCjc4PhfS=> NGSwN|Z,OTBizszN MkeyTWM2OD14IH7N M1PCRVE2PDh{OUK5
CPT-K5 NHvnPYZkgXSxdH;4bYNqfHliYYPzZZk> MVP+NVAh|ryP M1;4ZWlEPTB-MUCg{txO M1exSFE2PDh{OUK5
P388 MW\jfZRwfG:6aXPpeJkh[XO|YYm= NETPSYd,OTBizszN M4TVemlEPTB;MUSgcm0> M3naZlE2PDh{OUK5
P388/CPT45 MW\jfZRwfG:6aXPpeJkh[XO|YYm= M3f6PJ4yOCEQvF2= NIXlXWpKSzVyPkGwJO69VQ>? NYG3eJlYOTV2OEK5Nlk>
KB3-1 MV3jfZRwfG:6aXPpeJkh[XO|YYm= NYjCWItMhjFyIN88US=> MWTJR|UxRTRyIH7N NVny[ZY2OTV2OEK5Nlk>
KBV-1 + MDR1 NUj4WXp2[3m2b4TvfIlkcXS7IHHzd4F6 NX;Y[2U4hjFyIN88US=> NUXocIdDUUN3ME20OFAhdk1? Ml3aNVU1QDJ7Mkm=
KBH MoOyZ5l1d3SxeHnjbZR6KGG|c3H5 M3\rNJ4yOCEQvF2= NFP6dm9KSzVyPUS0NEBvVQ>? MYmxOVQ5Ojl{OR?=
HOP-62 MnnQZ5l1d3SxeHnjbZR6KGG|c3H5 NFzNeXF,OTBizszN MoL1S2k2OD1zMDDuUS=> NHy0c2syPTVyOUG2OC=>
HCT-116 MUjjfZRwfG:6aXPpeJkh[XO|YYm= NUf0[ZMxhjFyIN88US=> MUXHTVUxRTNyIH7N MnvBNVU2ODlzNkS=
F-539 NXXSeFZR[3m2b4TvfIlkcXS7IHHzd4F6 MUD+NVAh|ryP NHm4N4xIUTVyPUGwJI5O NIGydngyPTVyOUG2OC=>
UACC-62 NH\mdXFkgXSxdH;4bYNqfHliYYPzZZk> M2L2d54yOCEQvF2= MYHHTVUxRTFyIH7N MYqxOVUxQTF4NB?=
OVCAR-3 MV3jfZRwfG:6aXPpeJkh[XO|YYm= MlLNglExKM7:TR?= NWDlSnVmT0l3ME2yNlAhdk1? NGXBSWEyPTVyOUG2OC=>
SN12C NUHae5lp[3m2b4TvfIlkcXS7IHHzd4F6 NILJNWx,OTBizszN NVrETpNIT0l3ME2yNEBvVQ>? NV;3[4dGOTV3MEmxOlQ>
DU-145 M2fQVYN6fG:2b4jpZ4l1gSCjc4PhfS=> M{\HXp4yOCEQvF2= MkLpS2k2OD1zMDDuUS=> Ml[3NVU2ODlzNkS=
MDA-MB-435 M3vWb4N6fG:2b4jpZ4l1gSCjc4PhfS=> M3TFTp4yOCEQvF2= M4HKcmdKPTB;NECgcm0> M37jc|E2PTB7MU[0
MT-4 NXzxfoNu[3m2b4TvfIlkcXS7IHHzd4F6 Mmq2TWM2OD12IH7N M{XvSFE4OjV2Nk[5
CCRF-CEMc NH7RepJkgXSxdH;4bYNqfHliYYPzZZk> NYjhfW1xUUN3ME2zJI5O MWmxO|I2PDZ4OR?=
WIL-2NSd MYfjfZRwfG:6aXPpeJkh[XO|YYm= NIDOWFNKSzVyPUWgcm0> MXuxO|I2PDZ4OR?=
CCRF-SB MYjjfZRwfG:6aXPpeJkh[XO|YYm= NGX4dYFKSzVyPUOgcm0> M4HHUlE4OjV2Nk[5
CRL 7065 NHzodpBkgXSxdH;4bYNqfHliYYPzZZk> MmHzTWM2OD12MECgcm0> M4rjZVE4OjV2Nk[5
SK-MEL-28b NGf5SHpkgXSxdH;4bYNqfHliYYPzZZk> NWr2eWZ1UUN3ME20NEBvVQ>? MV:xO|I2PDZ4OR?=
MCF-7 M3r4Z4N6fG:2b4jpZ4l1gSCjc4PhfS=> M3HWWmlEPTB;NECgcm0> MYKxO|I2PDZ4OR?=
SKMES-1 NYrNW4w5[3m2b4TvfIlkcXS7IHHzd4F6 MXHJR|UxRTFyIH7N MVGxO|I2PDZ4OR?=
HepG2 M133cIN6fG:2b4jpZ4l1gSCjc4PhfS=> NH;DWppKSzVyPUOwJI5O M3;y[VE4OjV2Nk[5
DU145 Mn;WZ5l1d3SxeHnjbZR6KGG|c3H5 NWfVUXZwUUN3ME2xNEBvVQ>? MUexO|I2PDZ4OR?=

... Click to View More Cell Line Experimental Data

In vivo Camptothecin (8 mg/kg) displays complete growth inhibition and regression in mice xenografts of various tumors, including colon, lung, breast, stomach, and ovary tumors. [3] In mice, combinations of Camptothecin (50 mg/kg) and TNF (5 and 7 μg/kg), but not Camptothecin alone, induces liver damage. [4]

Protocol

Kinase Assay:[2]
+ Expand

Topoisomerase I Cleavable Complex Assay:

Topoisomerase I is isolated from calf thymus and is devoid of topoisomerase II. All reactions are carried out in 10 mL volumes of reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 0.5 mM EDTA, and 30 pg/mL BSA) in microtiter plates. Camptothecin is dissolved in DMSO at 10 mg/mL and serially diluted in 96-well microtiter plates to which the 32P end-labeled pBR322 DNA and topoisomerase enzyme are added. The reaction mixture is incubated at room temperature for 30 min and then the reaction stopped by adding 2 mL of a mixture of sodium dodecyl sulfate and proteinase K (1.6% and 0.14 mg/mL final concentrations, respectively). The plates are heated at 50 °C for 30 min, 10 mL of standard stop mixture containing 0.45 N NaOH is added in order to generate single-stranded DNA, and the samples are electrophoresed in 1.5% agarose gels in TBE buffer. Gels are blotted on nitrocellulose paper, dried, and exposed to X-ray film. The units of cleavage are calculated from the autoradiographs and plotted against the log drug concentration. The IC50 values are then obtaine
Cell Research:[2]
+ Expand
  • Cell lines: U87MG, A549 and H838 cells
  • Concentrations: 0.17 nM–10 mM
  • Incubation Time: 48 hours
  • Method: Tumor cells are plated in 100 μL of medium in 96-well microtiter plates at a density of 1500 to 4000 cells per well and allowed to adhere overnight. Cells are incubated with Camptothecin for 48 hours and then with fresh medium for 48 hours. Camptothecin at each concentration is added in quadruplicate. Following a 4-hour incubation of treated cells with MTT, the reduced dye product is extracted from the cells with 0.2 mL of DMSO followed by 50 μL of Sorensen's buffer. The plates are shaken briefly, and the absorbance at 570 nm is read and quantitated. Curves are fitted to the MTT assay data using a four-parameter logistic equation.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Nude mice (NIH-I high fertility strain) bearing xenografts of CASE, SW48, DOY, SPA, and CLO cells
  • Formulation: Finely grounded and dispersed in intralipid 20% at 1 mg/mL by sonication
  • Dosages: 0–8 mg/kg
  • Administration: Administered via i.m. or i.v. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (8.61 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.35
Formula

C20H16N2O4

CAS No. 7689-03-4
Storage powder
in solvent
Synonyms NSC-100880

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02755311 Unknown status Hepatocellular Carcinoma Sun Yat-sen University March 2014 Phase 3
NCT02755311 Unknown status Hepatocellular Carcinoma Sun Yat-sen University March 2014 Phase 3
NCT01803269 Terminated Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer University of Chicago|National Cancer Institute (NCI) January 16 2013 Phase 2
NCT01803269 Terminated Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer University of Chicago|National Cancer Institute (NCI) January 16 2013 Phase 2
NCT01612546 Completed Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Squamous Cell Carcinoma of the Esophagus|Stage IIIB Esophageal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer City of Hope Medical Center|National Cancer Institute (NCI) November 2012 Phase 2
NCT01612546 Completed Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Squamous Cell Carcinoma of the Esophagus|Stage IIIB Esophageal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer City of Hope Medical Center|National Cancer Institute (NCI) November 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Camptothecin | Camptothecin supplier | purchase Camptothecin | Camptothecin cost | Camptothecin manufacturer | order Camptothecin | Camptothecin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID